Scarica l'app Stockscreener
0.357
5.91%
-0.0239
Dopo l'orario di chiusura:
.35
-0.007
-1.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World
Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World
Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth - TipRanks
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lexicon: Q4 Earnings Snapshot - KTEN
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue - Investing.com India
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - StockTitan
Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Market Perform” Rating at Leerink Partners - Defense World
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times
Lexicon Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Nasdaq
When Will Lexicon Pharmaceuticals Reveal Its 2024 Financial Performance? - StockTitan
Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m - Simply Wall St
Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss - News & Insights
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga
Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint - Marketscreener.com
Lexicon Pharmaceuticals stock tumbles after clinical study results By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com India
Lexicon advances pilavapadin into Phase 3 for diabetic pain - Investing.com India
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon advances pilavapadin into Phase 3 for diabetic pain By Investing.com - Investing.com South Africa
Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider.com
Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - StockTitan
Lexicon Pharma To Announce Topline Results From Phase 2b PROGRESS Study Today - Nasdaq
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain - Nasdaq
Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - StockTitan
Lexicon Pharmaceuticals, Inc. Announces Resignation of Praveen Tyle as Executive Vice President, Research and Development, Effective as of April 26, 2021 - Marketscreener.com
Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - Yahoo Finance
Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain - News & Insights
Merck: 4 No-Brainer Reasons to Buy This Dip - The Globe and Mail
Vantage Markets Partners with Scuderia Ferrari HP for a Multi-Year Sponsorship - The Globe and Mail
Peripheral Neuropathic Pain Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart
Peripheral Neuropathic Pain Market to Show Remarkable Growth - openPR
George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs - GlobeNewswire Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given "Buy" Rating at HC Wainwright - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
0.49%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):